Equities research analysts expect Zoetis Inc (NYSE:ZTS) to announce $1.51 billion in sales for the current quarter, Zacks reports. Four analysts have made estimates for Zoetis’ earnings, with estimates ranging from $1.50 billion to $1.53 billion. Zoetis reported sales of $1.42 billion during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The company is expected to issue its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Zoetis will report full-year sales of $6.20 billion for the current financial year, with estimates ranging from $6.15 billion to $6.23 billion. For the next year, analysts expect that the company will post sales of $6.60 billion, with estimates ranging from $6.51 billion to $6.67 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Zoetis.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The company’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 EPS.
In other Zoetis news, insider Kristin C. Peck sold 11,500 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $100.92, for a total transaction of $1,160,580.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Clinton A. Jr. Lewis sold 6,125 shares of the stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $91.96, for a total value of $563,255.00. Following the transaction, the insider now directly owns 45,512 shares of the company’s stock, valued at approximately $4,185,283.52. The disclosure for this sale can be found here. Insiders sold a total of 439,786 shares of company stock valued at $41,830,940 in the last ninety days. 0.29% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in ZTS. Oregon Public Employees Retirement Fund raised its holdings in shares of Zoetis by 9,042.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after acquiring an additional 14,178,765 shares during the last quarter. FMR LLC raised its holdings in shares of Zoetis by 209.7% during the fourth quarter. FMR LLC now owns 7,245,748 shares of the company’s stock valued at $619,801,000 after acquiring an additional 4,905,887 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis during the fourth quarter valued at approximately $404,080,000. Two Sigma Advisers LP raised its holdings in shares of Zoetis by 947.4% during the fourth quarter. Two Sigma Advisers LP now owns 1,149,111 shares of the company’s stock valued at $98,295,000 after acquiring an additional 1,039,400 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Zoetis by 167.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,607,247 shares of the company’s stock valued at $137,484,000 after acquiring an additional 1,005,212 shares during the last quarter. 90.84% of the stock is owned by institutional investors and hedge funds.
Shares of ZTS stock opened at $101.25 on Wednesday. The stock has a market capitalization of $48.96 billion, a PE ratio of 32.35, a P/E/G ratio of 2.54 and a beta of 0.91. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. Zoetis has a 52-week low of $78.90 and a 52-week high of $103.97.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.